Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.81 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | BLM | P54132 | 1/20 | 0.58 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6377387 | 1.00 | CYP1A2 (0.81) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL2338208 | 1.00 | CYP1A2 (0.81) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL7416439 | 1.00 | CYP1A2 (0.81) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL3866042 | 1.00 | CYP1A2 (0.81) | CYP1A2USP2ALDH1A1LMNATSHR | |
| Hydrochloric Acid SCHEMBL6376597 | 0.98 | CYP1A2 (0.78) | CYP1A2USP2ALDH1A1LMNATSHR | |
| Hydrochloric Acid SCHEMBL6376591 | 0.98 | CYP1A2 (0.78) | CYP1A2USP2ALDH1A1LMNATSHR | |
| Hydrochloric Acid SCHEMBL27548750 | 0.98 | CYP1A2 (0.78) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL5441593 | 0.90 | CYP1A2 (0.64) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL5434321 | 0.90 | CYP1A2 (0.64) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL5436210 | 0.90 | CYP1A2 (0.64) | CYP1A2USP2ALDH1A1LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 216 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4681116-B2 | — | — | 2011-05-11 | — | — | JP | claimed |
| US-20110039875-A1 | PHARAMACEUTICAL COMPOSITIONS FOR TREATING CHRONIC PAIN AND PAIN ASSOCIATED WITH NEUROPATHY | TRINITY LABORATORIES, INC. | 2011-02-17 | — | — | US | claimed |
| EP-2184986-A2 | PHARMACEUTICAL COMPOSITIONS FOR TREATING CHRONIC PAIN AND PAIN ASSOCIATED WITH NEUROPATHY | Trinity Laboratories, Inc. (US) | 2010-05-19 | — | — | EP | claimed |
| EP-1009399-B1 | GABA ANALOGS TO PREVENT AND TREAT GASTROINTESTINAL DAMAGE | WARNER LAMBERT CO (US) | 2010-03-24 | — | — | EP | claimed |
| WO-2009021058-A2 | PHARMACEUTICAL COMPOSITIONS FOR TREATING CHRONIC PAIN AND PAIN ASSOCIATED WITH NEUROPATHY | TRINITY LABORTORIES, INC. (US) | 2009-02-12 | — | — | WO | claimed |
| JP-4216713-B2 | — | — | 2009-01-28 | — | — | JP | claimed |
| US-7423169-B2 | Methods for synthesis of acyloxyalkyl derivatives of GABA analogs | XENOPORT, INC. (US) | 2008-09-09 | — | — | US | claimed |
| WO-2007120485-A2 | METHODS OF TREATING PAIN WITH ALKYLXANTHINES AND ANTIEPILEPTICS AND COMPOSITIONS FOR USE THEREFOR | CINERGEN, LLC (US) | 2007-10-25 | — | — | WO | claimed |
| US-7232924-B2 | Methods for synthesis of acyloxyalkyl derivatives of GABA analogs | XENOPORT, INC. (US) | 2007-06-19 | — | — | US | claimed |
| JP-3884486-B2 | — | — | 2007-02-21 | — | — | JP | claimed |
| US-6127418-A | USING, E.G. PREGABALAN, GAGAPENTIN, FOR A PATIENT WHO IS OR WILL RECEIVE NSAID THERAPY OR ALCOHOL ABUSE THERAPY; INFLAMMATORY BOWEL DISORDER; IRRITABLE BOWEL SYNDROME; CROHN'S DISEASE, ILEITIS, ISCHEMIC BOWEL DISEASE | WARNER-LAMBERT COMPANY (US) | 2000-10-03 | — | — | US | claimed |
| US-6103932-A | USEFUL AS AGENTS IN THE TREATMENT OF EPILEPSY, FAINTNESS ATTACKS, HYPOKINESIA, CRANIAL DISORDERS, NEURODEGENERATIVE DISORDERS, DEPRESSION, ANXIETY, PANIC, PAIN, AND NEUROPATHOLOGICAL DISORDERS | WARNER-LAMBERT COMPANY (US) | 2000-08-15 | — | — | US | claimed |
| EP-1009399-A1 | GABA ANALOGS TO PREVENT AND TREAT GASTROINTESTINAL DAMAGE | WARNER-LAMBERT COMPANY LLC (US) | 2000-06-21 | — | — | EP | claimed |
| EP-0994704-A1 | USE OF GABA ANALOGS SUCH AS GABAPENTIN IN THE MANUFACTURE OF A MEDICAMENT FOR TREATING INFLAMMATORY DISEASES | WARNER-LAMBERT COMPANY (US) | 2000-04-26 | — | — | EP | claimed |
| EP-0974351-A2 | Medicament for preventing and treating gastrointestinal damage | JOUVEINAL (FR) | 2000-01-26 | — | — | EP | claimed |
| WO-1999008671-A1 | GABA ANALOGS TO PREVENT AND TREAT GASTROINTESTINAL DAMAGE | WARNER-LAMBERT COMPANY (US) | 1999-02-25 | — | — | WO | claimed |
| WO-1999008670-A1 | GABA ANALOGS TO PREVENT AND TREAT GASTROINTESTINAL DAMAGE | GUGLIETTA, ANTONIO | 1999-02-25 | — | — | WO | claimed |
| EP-0888286-A1 | NOVEL SUBSTITUTED CYCLIC AMINO ACIDS AS PHARMACEUTICAL AGENTS | WARNER-LAMBERT COMPANY (US) | 1999-01-07 | — | — | EP | claimed |
| WO-1998058641-A1 | USE OF GABA ANALOGS SUCH AS GABAPENTIN IN THE MANUFACTURE OF A MEDICAMENT FOR TREATING INFLAMMATORY DISEASES | WARNER-LAMBERT COMPANY (US) | 1998-12-30 | — | — | WO | claimed |
| WO-1997033858-A1 | NOVEL SUBSTITUTED CYCLIC AMINO ACIDS AS PHARMACEUTICAL AGENTS | WARNER-LAMBERT COMPANY (US) | 1997-09-18 | — | — | WO | claimed |